Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

BACKGROUND: Fulvestrant (FUL) and the combination of everolimus and exemestane (EVE-EXE) were the options to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) patients who were refractory to aromatase inhibitors (AIs). The...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ther Clin Risk Manag
Glavni autori: Li, Yi, Xie, Yizhao, Gong, Chengcheng, Zhao, Yannan, Zhang, Jian, Zhang, Sheng, Wang, Leiping, Chen, She, Hu, Xichun, Wang, Biyun
Format: Artigo
Jezik:Inglês
Izdano: Dove 2020
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7335268/
https://ncbi.nlm.nih.gov/pubmed/32636632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S255365
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items